Status of immune-based therapies in HIV infection and AIDS.

作者: J. L. FAHEY , R. SCHOOLEY

DOI: 10.1111/J.1365-2249.1992.TB03029.X

关键词: Acquired immunodeficiency syndrome (AIDS)Viral diseaseImmunologyImmunotherapyPathogenesisAntibodyCytokineImmunopathologyMedicineImmune system

摘要: As our understanding of HIV disease pathogenesis progresses, approaches to immune-based therapy are evolving. Initial therapies aiming alter immune function in patients with infection have had mixed results. Clinical benefit the trials so far has not been dramatic, although studies still at an early stage, and correct protocols for various agents or combinations yet be established. might expected, where apparent occurred, it more obvious those whose system was intact.

参考文章(16)
Jim M. Koeller, Jill K. Bruton, Recombinant Interleukin-2 Pharmacotherapy. ,vol. 14, pp. 635- 656 ,(1994) , 10.1002/J.1875-9114.1994.TB04156.X
Court Pedersen, Eric Sandström, Carsten Sand Petersen, Gunnar Norkrans, Jan Gerstoft, Anders Karlsson, Knud Chr. Christensen, Charles Håkansson, PehrOlov Pehrson, Jens Ole Nielsen, Hans Jessen Jürgensen, , The Efficacy of Inosine Pranobex in Preventing the Acquired Immunodeficiency Syndrome in Patients with Human Immunodeficiency Virus Infection New England Journal of Medicine. ,vol. 322, pp. 1757- 1763 ,(1990) , 10.1056/NEJM199006213222501
Robert R Redfield, Deborah L Birx, Nzeera Ketter, Edmund Tramont, Victoria Polonis, Charles Davis, John F Brundage, Gale Smith, Steven Johnson, Arnold Fowler, Thomas Wierzba, Avigdor Shafferman, Franklin Volvovitz, Charles Oster, Donald S Burke, Military Medical Consortium for Applied Retroviral Research, A Phase I Evaluation of the Safety and Immunogenicity of Vaccination with Recombinant gp160 in Patients with Early Human Immunodeficiency Virus Infection New England Journal of Medicine. ,vol. 324, pp. 1677- 1684 ,(1991) , 10.1056/NEJM199106133242401
E. S. Daar, X. L. Li, T. Moudgil, D. D. Ho, High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 87, pp. 6574- 6578 ,(1990) , 10.1073/PNAS.87.17.6574
Ronald T. Mitsuyasu, Interferon alpha in the treatment of AIDS-related Kaposi's sarcoma British Journal of Haematology. ,vol. 79, pp. 69- 73 ,(1991) , 10.1111/J.1365-2141.1991.TB08124.X
David H. Schwartz, Gail Skowron, Thomas C. Merigan, Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndromes. ,vol. 4, pp. 11- 23 ,(1991) , 10.1097/00126334-199101000-00002
EVAN M. HERSH, CAROLE Y. FUNK, KAY L. RYSCHON, ESKILD A. PETERSEN, DONALD E. MOSIER, Effective therapy of the LP-BM5 murine retrovirus-induced lymphoproliferative immunodeficiency disease with diethyldithiocarbamate. AIDS Research and Human Retroviruses. ,vol. 7, pp. 553- 561 ,(1991) , 10.1089/AID.1991.7.553
Susan E Krown, Jonathan WM Gold, Donna Niedzwiecki, Denise Bundow, Neal Flomenberg, Bernd Gansbacher, Bruce J Brew, Interferon-α with Zidovudine: Safety, Tolerance, and Clinical and Virologic Effects in Patients with Kaposi Sarcoma Associated with the Acquired Immunodeficiency Syndrome (AIDS) Annals of Internal Medicine. ,vol. 112, pp. 812- 821 ,(1990) , 10.7326/0003-4819-112-11-812